Terms: = Breast cancer AND PDGFRB, JTK12, 5159, P09619, ENSG00000113721, PDGF-R-beta, PDGFR1, CD140B, PDGFR, CD140b AND Treatment
81 results:
1. The relationship between cancer associated fibroblasts biomarkers and prognosis of breast cancer: a systematic review and meta-analysis.
Cui M; Dong H; Duan W; Wang X; Liu Y; Shi L; Zhang B
PeerJ; 2024; 12():e16958. PubMed ID: 38410801
[TBL] [Abstract] [Full Text] [Related]
2. Prognostic Markers in Tyrosine Kinases Specific to Basal-like 2 Subtype of Triple-Negative breast cancer.
Limsakul P; Choochuen P; Jungrungrueang T; Charupanit K
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338684
[TBL] [Abstract] [Full Text] [Related]
3. Mechanism of Erianin anti-triple negative breast cancer based on transcriptomics methods and network pharmacology.
Li M; Zhao Y; Li H; Kang S; Deng X; Sheng M
Aging (Albany NY); 2024 Feb; 16(3):2848-2865. PubMed ID: 38329441
[TBL] [Abstract] [Full Text] [Related]
4. Natural History of Germline BRCA1 Mutated and BRCA Wild-type Triple-negative breast cancer.
Gardi N; Chaubal R; Parab P; Pachakar S; Kulkarni S; Shet T; Joshi S; Kembhavi Y; Chandrani P; Quist J; Kowtal P; Grigoriadis A; Sarin R; Govindarajan R; Gupta S
Cancer Res Commun; 2024 Feb; 4(2):404-417. PubMed ID: 38315150
[TBL] [Abstract] [Full Text] [Related]
5. The prognostic and predictive values of differential expression of exosomal receptor tyrosine kinases and associated with the PI3K/AKT/mTOR signaling in breast cancer patients undergoing neoadjuvant chemotherapy.
Guney Eskiler G; Kazan N; Haciefendi A; Deveci Ozkan A; Ozdemir K; Ozen M; Kocer HB; Yilmaz F; Kaleli S; Sahin E; Bilir C
Clin Transl Oncol; 2023 Feb; 25(2):460-472. PubMed ID: 36181664
[TBL] [Abstract] [Full Text] [Related]
6. Her2/EGFR-pdgfr pathway aberrations associated with tamoxifen response in metastatic breast cancer patients.
Malash I; Mansour O; Gaafar R; Shaarawy S; Abdellateif MS; Ahmed OS; Zekri AN; Bahnassy A
J Egypt Natl Canc Inst; 2022 Jul; 34(1):31. PubMed ID: 35871690
[TBL] [Abstract] [Full Text] [Related]
7. Diverse roles of tumor-stromal PDGFB-to-pdgfrβ signaling in breast cancer growth and metastasis.
Shah S; Sizemore GM
Adv Cancer Res; 2022; 154():93-140. PubMed ID: 35459473
[TBL] [Abstract] [Full Text] [Related]
8. Recent Advances in Epidermal Growth Factor Receptor Inhibitors (EGFRIs) and their Role in the treatment of cancer: A Review.
Unnisa A; Chettupalli AK; Hussain T; Kamal MA
Anticancer Agents Med Chem; 2022; 22(20):3370-3381. PubMed ID: 35400324
[TBL] [Abstract] [Full Text] [Related]
9. PDGF-R inhibition induces glioblastoma cell differentiation via DUSP1/p38
Lane R; Cilibrasi C; Chen J; Shah K; Messuti E; Mazarakis NK; Stebbing J; Critchley G; Song E; Simon T; Giamas G
Oncogene; 2022 May; 41(19):2749-2763. PubMed ID: 35393545
[TBL] [Abstract] [Full Text] [Related]
10. Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative breast cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial.
Chen L; Jiang YZ; Wu SY; Wu J; Di GH; Liu GY; Yu KD; Fan L; Li JJ; Hou YF; Hu Z; Chen CM; Huang XY; Cao AY; Hu X; Zhao S; Ma XY; Xu Y; Sun XJ; Chai WJ; Guo X; Chen X; Xu Y; Zhu XY; Zou JJ; Yang WT; Wang ZH; Shao ZM
Clin Cancer Res; 2022 Jul; 28(13):2807-2817. PubMed ID: 35247906
[TBL] [Abstract] [Full Text] [Related]
11. Neuropilin-1 is over-expressed in claudin-low breast cancer and promotes tumor progression through acquisition of stem cell characteristics and RAS/MAPK pathway activation.
Tang YH; Rockstroh A; Sokolowski KA; Lynam LR; Lehman M; Thompson EW; Gregory PA; Nelson CC; Volpert M; Hollier BG
Breast Cancer Res; 2022 Jan; 24(1):8. PubMed ID: 35078508
[TBL] [Abstract] [Full Text] [Related]
12.
Sakle NS; More SA; Mokale SN
Nutr Cancer; 2022; 74(6):2222-2234. PubMed ID: 34612094
[TBL] [Abstract] [Full Text] [Related]
13. High pdgfrb Expression Predicts Resistance to Radiotherapy in DCIS within the SweDCIS Randomized Trial.
Strell C; Folkvaljon D; Holmberg E; Schiza A; Thurfjell V; Karlsson P; Bergh J; Bremer T; Akslen LA; Wärnberg F; Östman A
Clin Cancer Res; 2021 Jun; 27(12):3469-3477. PubMed ID: 33952629
[TBL] [Abstract] [Full Text] [Related]
14. AKT1-CREB stimulation of pdgfrα expression is pivotal for PTEN deficient tumor development.
Wan X; Zhou M; Huang F; Zhao N; Chen X; Wu Y; Zhu W; Ni Z; Jin F; Wang Y; Hu Z; Chen X; Ren M; Zhang H; Zha X
Cell Death Dis; 2021 Feb; 12(2):172. PubMed ID: 33568640
[TBL] [Abstract] [Full Text] [Related]
15. Gain of HIF1 Activity and Loss of miRNA
Wyss CB; Duffey N; Peyvandi S; Barras D; Martinez Usatorre A; Coquoz O; Romero P; Delorenzi M; Lorusso G; Rüegg C
Cancer Res; 2021 Feb; 81(3):594-605. PubMed ID: 33526470
[TBL] [Abstract] [Full Text] [Related]
16. Inhibition of platelet-derived growth factor C and their receptors additionally increases doxorubicin effects in triple-negative breast cancer cells.
Kim S; You D; Jeong Y; Yoon SY; Kim SA; Lee JE
Eur J Pharmacol; 2021 Mar; 895():173868. PubMed ID: 33460613
[TBL] [Abstract] [Full Text] [Related]
17. Broadening Drug Design and Targets to Tumor Microenvironment? cancer-Associated Fibroblast Marker Expression in cancers and Relevance for Survival Outcomes.
Dzobo K; Dandara C
OMICS; 2020 Jun; 24(6):340-351. PubMed ID: 32496971
[TBL] [Abstract] [Full Text] [Related]
18. Regulation of docetaxel chemosensitivity by NR2F6 in breast cancer.
Zhang J; Meng H; Zhang M; Zhang C; Huang M; Yan C; Wang Z; Hou L; Yang L; Ling R
Endocr Relat Cancer; 2020 May; 27(5):309-323. PubMed ID: 32203934
[TBL] [Abstract] [Full Text] [Related]
19. Regorafenib sensitizes human breast cancer cells to radiation by inhibiting multiple kinases and inducing DNA damage.
Mehta M; Griffith J; Panneerselvam J; Babu A; Mani J; Herman T; Ramesh R; Munshi A
Int J Radiat Biol; 2021; 97(8):1109-1120. PubMed ID: 32052681
[TBL] [Abstract] [Full Text] [Related]
20. MYC regulates fatty acid metabolism through a multigenic program in claudin-low triple negative breast cancer.
Casciano JC; Perry C; Cohen-Nowak AJ; Miller KD; Vande Voorde J; Zhang Q; Chalmers S; Sandison ME; Liu Q; Hedley A; McBryan T; Tang HY; Gorman N; Beer T; Speicher DW; Adams PD; Liu X; Schlegel R; McCarron JG; Wakelam MJO; Gottlieb E; Kossenkov AV; Schug ZT
Br J Cancer; 2020 Mar; 122(6):868-884. PubMed ID: 31942031
[TBL] [Abstract] [Full Text] [Related]
[Next]
